

10/062824

6248.200-US  
US Patent Application No. 10/068,224

Page 5 of 5  
December 21, 2004


### REMARKS

This Amendment after Final is made in response to the final Office Action dated February 18, 2004. An Advisory Action was mailed on October 26, 2004, noting that Applicants previously submitted Amendment in response to this Office Action was not entered. The undersigned unfortunately only recently became aware of this Advisory Action and the status of this case as unintentionally abandoned (which actually appears to have occurred more than two months prior to the mailing of the Advisory Action). Accordingly, this Amendment is based on the claims as they stood at the Office Action of February 18, 2004, and is submitted concurrently with a Petition to Revive the application.

This Amendment cancels all of the non-allowed claims, thereby appropriately responding to the final Office Action by putting the case in condition for allowance after the unintentional abandonment (see, e.g., MPEP 711.03(c)).

In view of the claim amendments and remarks made herein, it is respectfully submitted that all of the pending claims are in condition for allowance. Early action to that end is respectfully requested. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner is invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Date: December 21, 2004

Len S. Smith, Reg. No. 43,139  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800

Please use the following customer number for all correspondence regarding this application.

\*23650\*

PATENT TRADEMARK OFFICE